Currently out of the existing stock ratings of Whitney Ijem, 143 are a BUY (80.79%), 26 are a HOLD (14.69%), 8 are a SELL (4.52%).

Whitney Ijem

Work Performance Price Targets & Ratings Chart

Analyst Whitney Ijem, currently employed at CANACCORD, carries an average stock price target met ratio of 33.24% that have a potential upside of 27.29% achieved within 277 days.

Whitney Ijem’s has documented 344 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RARE, Ultragenyx at 18-Sep-2026.

Wall Street Analyst Whitney Ijem

Analyst best performing recommendations are on KRYS (KRYSTAL BIOTECH).
The best stock recommendation documented was for KRYS (KRYSTAL BIOTECH) at 5/30/2019. The price target of $48 was fulfilled within 48 days with a profit of $16 (50%) receiving and performance score of 10.42.

Average potential price target upside

of $106.3 (48.61%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $34.62 (65.85%) on KRYS (KRYSTAL BIOTECH).
of $27.81 (71.67%) on RYTM (RHYTHM PHARMACEUTICALS).

SRPT Sarepta Therapeutics GBIO Generation Bio Co PASG Passage Bio RCKT Rocket Pharmaceuticals RGLS Regulus Therapeutics TNYA Tenaya Therapeutics ALNY Alnylam Pharmaceuticals BMRN Biomarin Pharmaceutical GILD Gilead Sciences KRYS Krystal Biotech RYTM Rhythm Pharmaceuticals SGMO Sangamo Therapeutics TSHA Taysha Gene Therapies VRTX Vertex Pharmaceuticals ARCT Arcturus Therapeutics Holdings NTLA Intellia Therapeutics SGTX Sigilon Therapeutics VERV Verve Therapeutics RARE Ultragenyx AXGT Sio Gene Therapies ONCE Spark Therapeutics WVE Wave Life Sciences Ltd GUTS Fractyl Health, Common Stock AVRO AVROBIO BBIO BridgeBio Pharma NGNE Neurogene OCGN Ocugen

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Biren Amin (PIPER SANDLER)

Hold Since 23-Jun-2025

$20

$-0.11 (-0.55%)

$16

2 months 20 days ago
(09-Jul-2026)

7/17 (41.18%)

$-0.52 (-2.53%)

Please subscribe to see extended stock data

Yigal Nochomovitz (CITI)

Sell Since 24-Jul-2025

$13

$-3.85 (-22.85%)

6 months 3 days ago
(26-Mar-2026)

0/2 (0%)

$-8.68 (-40.04%)

Please subscribe to see extended stock data

Gil Blum (NEEDHAM)

Sell Since 22-Jul-2025

6 months 3 days ago
(26-Mar-2026)

14/35 (40%)

$28.03 (127.58%)

364

Please subscribe to see extended stock data

Kostas Biliouris (OPPENHEIMER)

Buy Since 19-Mar-2026

$37

$20.15 (119.58%)

$50

6 months 10 days ago
(19-Mar-2026)

0/16 (0%)

$20.35 (122.22%)

Please subscribe to see extended stock data

Uy Ear (MIZUHO)

Buy Since 13-Mar-2026

$31

$14.15 (83.98%)

$19

6 months 16 days ago
(13-Mar-2026)

4/14 (28.57%)

$14.6 (89.02%)

322

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Whitney Ijem most bullish on?

Potential upside of $137.69 has been obtained for NGNE (NEUROGENE)

Which stock is Whitney Ijem most reserved on?

Potential downside of -$85.67 has been obtained for VRTX (VERTEX PHARMACEUTICALS)

What Year was the first public recommendation made by Whitney Ijem?

On 2018